Protein and resistance training are the missing half
These tools provide motivation, accountability, and practical guidance that complement clinical care, helping individuals stay engaged and focused on their goals
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
That is roughly double to triple the discontinuation rate seen with semaglutide
Exubera (insulin human [rDNA origin] Inhalation Powder September 2008
However, adding more compounds increases protocol complexity and makes it harder to track which peptide contributes to specific effects